Search Results for: PERSONALIZED MEDICINE Targeted Personalized Therap
Articles
PERSONALIZED MEDICINE - Targeted, Personalized Therapy is the Future of Chronic Disease Therapeutics November 17, 2014
The global life sciences sector is employing new research and development (R&D) and business models to cost effectively deliver innovation,...Palisade Bio Enters Strategic Collaboration With Strand Life Sciences to Advance Precision Medicine Approach April 23, 2024
Partnership marks a significant value-driving milestone in Palisade Bio’s mission to redefine UC treatment through targeted interventions based on PDE4-related biomarkers….
BC Platforms & NTT Group Announce Official Opening Ceremony for Exclusive Collaboration & Launch of Japanese Precision Medicine Platform April 15, 2024
BC Platforms (BCP) recently announces an exclusive collaboration with NTT Life Science Corporation, a company in the medical field of the NTT Group, to accelerate data-driven….
VACCINE DEVELOPMENT - Therapeutic Vaccines Development: At the Edge of a New Revolution March 28, 2024
Mario Davinelli, PhD, Narcisa Mesaros, MD, David Morland, and Judith Neville, PhD, say therapeutic vaccines are an exciting area of research that has the potential to revolutionize the way we treat diseases.
Bayer & Thermo Fisher Scientific Collaborate to Increase Patient Access to Precision Cancer Medicines March 20, 2024
Bayer AG and Thermo Fisher Scientific Inc. recently announced they will develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together....ARTIFICIAL INTELLIGENCE PLATFORM - Advancing Precision Medicine With bfLEAP™: Next Generation AI for Drug Development January 26, 2024
Thomas Hazel, PhD, and JT Koffenberger explore the technical architecture and capabilities of bfLEAP, delving into its ML algorithms, proprietary clustering techniques, and visually understandable outputs, examine some of the potential use cases for the platform in drug development, and discuss future developments.
Henlius & Sermonix Announce Strategic Collaboration & Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene January 11, 2024
Sermonix Pharmaceuticals Inc. and Shanghai Henlius Biotech, Inc. recently announced a strategic collaboration agreement in which Henlius will receive exclusive...Catalent Launches New Oral Developability Assessment & Manufacturing Solution to Advance Targeted Protein Degrader Programs March 29, 2023
Catalent recently announced the launch of the ProteoSuite Oral suite, which allows the rational selection of orally developable targeted protein degrader (TPD) candidates and their advancement into….
Akoya Biosciences to Partner With Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature Test Into a Companion Diagnostic June 28, 2022
Akoya Biosciences, Inc. and Acrivon Therapeutics, Inc. recently announced an agreement to co-develop, validate, and commercialize Acrivon’s OncoSignature test, a first-of-its-kind...Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial & Urothelial Cancer Patients June 22, 2022
Acrivon Therapeutics, Inc. recently announced the US FDA has cleared the company's Investigational New Drug (IND) application for its lead...EXOSOMES - The Next Evolution in Therapy Delivery Beyond the Cell Membrane: The Promise of Exosomes January 17, 2022
Linda Marbán, PhD, says perhaps the best way to get past the cell membrane is to deliver contents the same way that cells send information to each other. And that is by the exosome, which in the case of targeted therapy delivery, has been identified as an alternative that shows powerful promise.
SomaLogic & Twist Bioscience Corporation Announce Partnership to Discover Novel Therapeutic Targets & Antibodies August 23, 2021
CM Life Sciences II and SomaLogic, Inc., and Twist Bioscience Corporation recently announced a collaboration aimed at creating novel antibodies and enabling innovative drug discovery based on….
ASSAY DEVELOPMENT - Case Study: How Custom Assay Development Helped Spur Precision Medicine Research in Multiple Myeloma October 1, 2020
Steven Gross, MS, provides a behind-the-scenes look at the CMMC assay development process (from 2010 through today) to show how pharmaceutical companies can effectively partner with a laboratory to design customized assays that complement their drug discovery and development programs.
IM Therapeutics Announces First Patient Dosed in Phase 1 Study of its Lead Drug for Type 1 Diabetes July 1, 2020
ImmunoMolecular Therapeutics, Inc. recently announced the dosing of the first patient in a Phase 1 study of IMT-002, an oral small molecule drug designed as a selective….
REGENERATIVE MEDICINE - Cell Therapy - The Quest for Finding the Cure November 12, 2018
Aarti Chitale, MBA, believes as the therapeutic landscape evolves and transitions toward personalized and value-based care, regenerative medicine will play an increasingly important role, and moreover, the success of these therapies offers promising opportunities for previously untreated diseases areas.
EXECUTIVE INTERVIEW - BriaCell Therapeutics: Recognizing the Power of Targeted Immunotherapies October 1, 2018
Dr. William “Bill” Williams, MD, President and CEO of BriaCell Therapeutics, discusses the value of targeted immunotherapies in the biopharmaceutical industry.
GENE-EDITING TECHNOLOGY - How CRISPR-Cas9 Technology Will Play a Vital Role in the Future of Human Therapeutics & Drug Discovery January 8, 2018
Kevin Holden, PhD, explores how this technology can be utilized in research efforts toward the development of new therapies and how it will play a vital role in the future of biopharma and drug discovery.
Felicitex Therapeutics & Selvita Initiate Strategic Collaboration November 10, 2014
Felicitex Therapeutics and Selvita recently announced they have entered into a strategic collaboration to develop breakthrough personalized cancer therapeutics for...MARKET BRIEF - The Market for Type 2 Diabetes Therapeutics - Key Findings From a Recent Analysis of Global Drug Development Efforts November 19, 2013
Debbie Toscano, Senior Industry Analyst, Frost & Sullivan, summarizes key findings of Frost & Sullivan’s recent analysis of the type 2 diabetes therapeutics market, which examines in detail the insulin and non-insulin segments of this market on a global level.
MARKET BRIEF - Controlled Release Technologies: Advancing Toward Targeting Therapeutics June 10, 2013
Frost & Sullivan Analyst Cecilia Van Cauwenberghe, MS, reviews a few recent innovative approaches to controlled release technologies with a focus on some of the therapeutic areas most relevant to the current pharmaceuticals market.